Loading field map
Healthcare markets are the systems—both actual and theoretical—through which medical goods and services are produced, allocated, priced, and consumed. The subfield of health economics that studies them asks a deceptively simple question: when does treating health care like a market work, when does it fail, and what should be done in each case? The stakes are unusually high because the commodity in question is not a typical one. Health is not a luxury good that people can simply choose to forgo; illness is often unpredictable, catastrophic, and unevenly distributed across the population. These features create persistent tensions between the logic of markets—efficiency, competition, consumer sovereignty—and the goals of health policy—access, equity, and financial protection.
To understand healthcare markets, one must first understand why health care resists ordinary market analysis. In a textbook market, buyers and sellers exchange well-defined goods, buyers have good information about what they are purchasing, and prices adjust to balance supply and demand. Health care violates each of these conditions in fundamental ways.
The first violation concerns information. Patients typically know far less about their medical conditions and treatment options than the physicians who treat them. This is not a minor asymmetry that can be corrected with better labeling; it is intrinsic to the product. A patient cannot easily shop for a diagnosis the way one shops for a television, because the patient does not know what is wrong, what the options are, or what the outcomes will be. The physician acts simultaneously as the patient's advisor and the supplier of services, creating a conflict of interest that economists call supplier-induced demand: the provider may recommend more care than is medically necessary because the provider benefits financially from providing it.
The second violation concerns uncertainty. Illness is unpredictable at the individual level, and the costs of treatment can be enormous. This is why health insurance exists, but insurance itself creates a new set of market problems. When people are insured, they face lower out-of-pocket prices for care, so they may consume more care than they would if they paid the full cost—a phenomenon known as moral hazard. At the same time, people who know they are likely to need care are more likely to buy insurance, a problem called adverse selection. If insurers cannot distinguish high-risk from low-risk enrollees, they must charge premiums that reflect the average risk, which drives healthy people out of the market, which raises the average risk further, potentially unraveling the insurance market entirely.
The third violation concerns externalities. Some health care produces benefits that spill beyond the individual patient. Vaccinations protect not only the vaccinated person but also the community by reducing transmission. Antibiotic treatment can reduce the spread of infectious disease. When such positive externalities exist, unregulated markets will tend to underprovide care because individuals do not capture the full social benefit of their consumption.
These features do not make markets impossible in health care, but they mean that the conditions for efficient market outcomes are rarely met. The central intellectual work of the subfield is to analyze how markets function under these distortions, to measure the size of the resulting inefficiencies, and to evaluate institutional responses—insurance design, provider payment, regulation, public provision—that might improve outcomes.
Health economics emerged as a distinct discipline in the mid-twentieth century, though its intellectual roots reach back further. Early economic thinking about health was scattered across discussions of public health, labor economics, and the economics of uncertainty. The field crystallized around a series of foundational contributions in the 1960s and 1970s that gave it a distinctive theoretical apparatus.
The most important of these was Kenneth Arrow's 1963 article on uncertainty and the welfare economics of medical care. Arrow did not simply list the ways health care deviates from the competitive ideal; he argued that many seemingly odd features of healthcare markets—nonprofit hospitals, professional licensing, the ethical norms of medicine—could be understood as institutional responses to the fundamental problems of uncertainty and information. This reframing was crucial: it moved the field from cataloging market failures to analyzing the logic of existing institutions.
A second foundational contribution came from Michael Grossman's model of health as a capital stock. In Grossman's framework, health is not just a state of being but a durable good that individuals invest in over their lifetimes. People demand health because it gives them utility directly and because it enables them to work and earn income. Medical care is one input into the production of health, alongside diet, exercise, and time. This model gave health economics a rigorous way to think about the demand for care as derived from a deeper demand for health itself.
A third strand came from the economics of insurance, which had been developing since the mid-twentieth century. The concepts of moral hazard and adverse selection were formalized in general insurance theory and then applied to health insurance specifically. Mark Pauly's work in the late 1960s argued that moral hazard in health insurance was not a market failure but a rational response to the fact that insurance lowers the effective price of care. This created a lasting debate about whether the welfare losses from moral hazard are real inefficiencies or simply the price of achieving risk protection.
These theoretical foundations were accompanied by the development of empirical tools. The RAND Health Insurance Experiment, conducted in the 1970s, was a landmark randomized trial that measured how people's use of health care responded to different levels of cost-sharing. Its finding that higher copayments reduce both necessary and unnecessary care—with little measurable effect on health for the average person—has shaped insurance design debates ever since. The experiment also demonstrated the feasibility of using rigorous empirical methods to answer policy-relevant questions about healthcare markets.
A large portion of healthcare market analysis concerns how insurance shapes the behavior of patients and the allocation of resources. The demand for health care is not a direct demand for a commodity but a demand mediated by insurance arrangements that determine the price the patient faces at the point of service.
The theory of insurance demand begins with risk aversion. If people dislike uncertainty about their future health expenses, they will be willing to pay more than their expected medical costs to obtain coverage that eliminates that uncertainty. The optimal insurance contract balances the benefit of risk reduction against the cost of moral hazard—the additional care consumed because insurance lowers its price. This tradeoff is the central normative question in insurance design. Deductibles, copayments, and coinsurance all exist as mechanisms to make patients bear some marginal cost of care, thereby limiting moral hazard, while still protecting them from catastrophic financial risk.
Adverse selection complicates this picture. If insurers cannot observe the health status of enrollees, they cannot price risk accurately. The classic theoretical result is that competitive insurance markets may fail to achieve efficient outcomes because low-risk individuals are driven out of pools that include high-risk individuals. This insight has motivated a wide range of policy interventions, from community rating regulations that require insurers to charge everyone the same premium, to risk adjustment mechanisms that transfer funds among insurers based on the health profile of their enrollees, to mandates that require everyone to purchase insurance.
The empirical literature on insurance markets has documented both the existence and the limits of these problems. Studies of Medicare Advantage, the private insurance option within the US Medicare program, have shown that insurers do engage in risk selection—attracting healthier enrollees and avoiding sicker ones—and that risk adjustment only partially compensates. Studies of the US Affordable Care Act's insurance exchanges have examined how premium subsidies and enrollment mandates affect the composition of risk pools. Outside the United States, countries with universal public insurance systems face different versions of these problems, often related to the design of supplementary private insurance and the incentives it creates for patients to shift between public and private sectors.
The supply side of healthcare markets is equally distinctive. Providers are not simple profit-maximizing firms, and the institutional arrangements governing their behavior are complex and varied across countries.
Physicians occupy a peculiar position. They are both the agents who make treatment decisions and the suppliers who receive payment for those decisions. The theory of supplier-induced demand suggests that physicians may use their informational advantage to steer patients toward more care than is clinically optimal, particularly when their income depends on the volume of services they provide. The empirical evidence on this is contested: it is difficult to distinguish induced demand from appropriate responses to patient needs, and the magnitude of the effect appears to vary across contexts. What is clear is that the payment system matters. Fee-for-service payment, which reimburses providers for each service rendered, creates incentives for overprovision. Capitation, which pays a fixed amount per patient regardless of services, creates incentives for underprovision. Salary payment removes the direct financial incentive but may reduce effort. No payment system is neutral; each creates its own pattern of distortions.
Hospitals add another layer of complexity. They are often nonprofit institutions, particularly in the United States, which raises questions about what objectives they pursue. Nonprofit hospitals may maximize quality, prestige, or community benefit rather than profit, but they still face competitive pressures. The empirical literature on hospital competition has produced a striking pattern of results: in the 1990s and 2000s, studies in the United States often found that more competition among hospitals was associated with higher prices, contrary to standard market logic. This was attributed to the fact that hospitals compete on quality and amenities to attract physicians and patients, and quality competition is costly. More recent evidence, particularly from the UK's National Health Service, where prices are regulated, has found that competition can improve quality and efficiency when the price dimension is removed. The lesson is that the effects of competition depend critically on the institutional environment in which it occurs.
Payment reform has been a major focus of policy and research. The shift from fee-for-service toward bundled payments—where a single payment covers all care for a particular episode—and capitation reflects an attempt to align provider incentives with efficiency and quality rather than volume. The evidence on these reforms is mixed: they can reduce costs in some settings, but they also create incentives to stint on care, to select healthier patients, and to shift costs to other payers. The design of payment systems remains one of the most active areas of applied research in the field.
Healthcare markets are often highly concentrated. Hospitals merge, physician practices consolidate, and insurers grow larger. The antitrust analysis of healthcare markets has become a specialized area within the field, with its own methods for defining relevant markets and measuring market power.
The distinctive feature of healthcare antitrust is that the product being sold is not a simple good but a complex service whose quality is difficult to measure. When two hospitals merge, the relevant question is whether the merger will allow the combined entity to raise prices to insurers, who pass those prices on to enrollees. But the merger might also improve quality, reduce costs through economies of scale, or allow the hospital to offer services that neither could offer alone. The empirical methods used to evaluate these tradeoffs—often based on analyzing how prices vary with market structure across geographic areas—have become increasingly sophisticated.
A related issue is the interaction between provider market power and insurer market power. In many regions, a small number of insurers negotiate with a small number of hospital systems. The outcome of these bilateral negotiations depends on the relative bargaining power of each side. Large insurers can use their enrollee base to demand lower prices from hospitals; large hospital systems can use their indispensability to demand higher prices from insurers. The empirical literature has found that both types of concentration are associated with higher prices, and that the effects are not symmetric: provider concentration tends to raise prices, while insurer concentration tends to lower them, though the latter effect is weaker and less consistent.
Every developed country has a substantial government role in healthcare markets, but the form of that role varies enormously. The United States relies primarily on private insurance and private provision, with public programs—Medicare for the elderly and disabled, Medicaid for the poor—covering about a third of the population. Most other developed countries have universal public insurance systems, though they differ in whether the insurance is administered by the government directly, by quasi-public bodies, or by regulated private insurers. Some countries, such as the United Kingdom, combine public insurance with public provision of hospital care; others, such as Germany and the Netherlands, combine public insurance with private provision.
The economics of these different arrangements is a central topic in the field. The key questions are comparative: How do different systems perform on measures of cost, quality, access, and equity? What are the incentive effects of different payment and regulatory regimes? How do patients respond to different cost-sharing arrangements, and how do providers respond to different payment arrangements?
The empirical literature on these questions has grown substantially with the availability of cross-country data. Studies comparing health system performance find that the United States spends far more per capita than other developed countries but does not achieve better health outcomes on most measures. This has motivated a large literature on why US healthcare costs are so high, with candidate explanations including higher prices for services and drugs, higher administrative costs, greater use of technology, and the fragmentation of the insurance system. No single explanation is fully satisfactory, and the debate remains active.
Regulation also plays a crucial role in healthcare markets beyond insurance and payment. Certificate-of-need laws in some US states require hospitals to obtain government approval before expanding or adding services, ostensibly to prevent duplication but potentially to protect incumbents from competition. Scope-of-practice regulations determine which tasks nurses, pharmacists, and other non-physician providers are allowed to perform, with significant implications for the supply of care and its cost. Drug pricing regulation, including the negotiation of prices by public payers, is a major policy issue in many countries. Each of these regulatory domains has generated its own empirical literature, but they share a common analytical framework: regulation is evaluated by its effects on prices, quantities, quality, and access, relative to the counterfactual of an unregulated market.
The contemporary study of healthcare markets is characterized by several converging trends. The first is the increasing availability of large-scale administrative data, which has enabled researchers to study healthcare markets with unprecedented precision. Claims data, electronic health records, and linked datasets allow for the measurement of prices, quantities, and outcomes at the level of individual patients, providers, and insurers. This has shifted the field toward quasi-experimental methods—difference-in-differences, regression discontinuity, instrumental variables—that can identify causal effects from observational data.
The second trend is the growing importance of behavioral economics. Traditional health economics assumed that patients and providers are rational actors who respond to financial incentives in predictable ways. Behavioral economics has complicated this picture by documenting systematic deviations from rationality: patients fail to choose the cheapest insurance plan even when the savings are large; they overuse emergency departments and underuse preventive care; they are influenced by the framing of choices and the defaults they are given. This has led to a new set of policy tools—nudges, default options, simplified information—that aim to improve decisions without restricting choice.
The third trend is the expansion of the field beyond its traditional focus on the United States and Western Europe. The study of healthcare markets in low- and middle-income countries has grown rapidly, driven by the recognition that most of the world's population lives in countries where healthcare markets function very differently. In many such countries, out-of-pocket payments dominate, insurance coverage is thin, and the informal sector plays a large role. The analytical tools of the field—moral hazard, adverse selection, supplier-induced demand—apply in these settings, but their manifestations and the appropriate policy responses can be quite different.
Open questions remain at the core of the field. The relationship between competition and quality in healthcare markets is still not fully understood, and the answer appears to depend on the details of payment and regulation. The optimal design of insurance—the right balance between risk protection and cost control—remains contested, with different countries making very different choices. The sources of healthcare cost growth, and the extent to which they reflect waste versus genuine improvement in health outcomes, are still debated. And the rapid development of new technologies—genomic medicine, artificial intelligence, digital health—raises questions about how healthcare markets will adapt to products that are even more information-intensive and uncertain than those of the past.
What unites these diverse lines of inquiry is a commitment to understanding healthcare markets as they actually are, not as idealized abstractions. The field has moved beyond the simple question of whether markets work in health care. The more productive question is which markets, under which institutional arrangements, for which services, and for which populations. The answer is rarely all or nothing; it is usually a matter of design.